Cytos Biotechnology Ltd of Switzerland said that it will seek shareholder approval for a rights issue valued at up to CHF 17.6 million (€14.3 million) in order to take its lead immunotherapy for allergic asthma through Phase 2b proof of concept. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
